<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35230221</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2222-1751</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Emerging microbes &amp; infections</Title>
          <ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>COVID-19 mass vaccination - an illustration of the impact of syringe choice on the effectiveness of mass vaccination campaigns.</ArticleTitle>
        <Pagination>
          <StartPage>804</StartPage>
          <EndPage>806</EndPage>
          <MedlinePgn>804-806</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2048968</ELocationID>
        <Abstract>
          <AbstractText>In order to optimise the operational implementation of mass vaccination policies, it is critical to consider not only the supply of vaccines as well as each element of the vaccination process. This study, which was conducted in a vaccination center clearly shows how the choice of a syringe reference used during the COVID-19 vaccination campaign influences the number of vaccine doses available. The results appear to be closely related to the type of vaccine used (COMIRNATY® and SPIKEVAX®). In this context, the choice of the right reference of syringe has major economic and organisational consequences on a global scale.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Roseline</LastName>
            <ForeName>Mazet</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-1841-6691</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmacy Unit, Grenoble University Hospital, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luc</LastName>
            <ForeName>Choisnard</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0003-4707-6531</Identifier>
            <AffiliationInfo>
              <Affiliation>University Grenoble Alpes DPM, Saint Martin d'Hères, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Julien</LastName>
            <ForeName>Leenhardt</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-2863-5011</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmacy Unit, Grenoble University Hospital, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olivier</LastName>
            <ForeName>Epaulard</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0001-8282-9522</Identifier>
            <AffiliationInfo>
              <Affiliation>Infectious Diseases Department, Grenoble University Hospital, Grenoble, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Groupe de recherche en infectiologie clinique, University Grenoble Alpes, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Etienne</LastName>
            <ForeName>Brudieu</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacy Unit, Grenoble University Hospital, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pierrick</LastName>
            <ForeName>Bedouch</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacy Unit, Grenoble University Hospital, Grenoble, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>University Grenoble Alpes TIMC, Grenoble, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Emerg Microbes Infect</MedlineTA>
        <NlmUniqueID>101594885</NlmUniqueID>
        <ISSNLinking>2222-1751</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013594" MajorTopicYN="N">Syringes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Mass vaccination</Keyword>
        <Keyword MajorTopicYN="N">medical device</Keyword>
        <Keyword MajorTopicYN="N">public health</Keyword>
        <Keyword MajorTopicYN="N">vaccination capacity</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35230221</ArticleId>
        <ArticleId IdType="pmc">PMC8920360</ArticleId>
        <ArticleId IdType="doi">10.1080/22221751.2022.2048968</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mofijur M, Fattah IMR, Alam MA, et al. . 
Impact of COVID-19 on the social, economic, environmental and energy domains: lessons learnt from a global pandemic. Sustainable Production and Consumption. 2021;26:343–359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7556229</ArticleId>
            <ArticleId IdType="pubmed">33072833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Center for Disease Control and Prevention . Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions [Internet]. Available from: https://www.ecdc.europa.eu/en/publications-data/interim-guidance-benefits-full-vaccination-against-covid-19-transmission.</Citation>
        </Reference>
        <Reference>
          <Citation>Cierco Seira C.
La vacuna-condición o el pasaporte de vacunación y su eventual encaje en un marco general de vacunación recomendada contra la COVID-19. Vacunas. 2021;22(2):82–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7908842</ArticleId>
            <ArticleId IdType="pubmed">33654478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Décret n° 2021-955 du 19 juillet 2021 modifiant le décret n° 2021-699 du 1er juin 2021 prescrivant les mesures générales nécessaires à la gestion de la sortie de crise sanitaire. 2021-955 Jul 19, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaddar M. Economic characteristics of vaccines and immunizations. World Health Organization. [Internet]. [cited 2021 Aug 16]. Available from: www.who.int/influenza_vaccines_plan/resources/session_2_kaddar.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>EMA . Summary of product characteristics - SPIKEVAX® dispersion for injection [Internet]. 2021 [cited 2021 Aug 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>EMA . Summary of product characteristics - COMIRNATY® concentrate for dispersion for injection [Internet]. 2021 [cited 2021 Aug 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>ISO . NF EN ISO 7886-1 - Sterile hypodermic syringes for single use — Part 1: Syringes for manual use. 2018.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
